[go: up one dir, main page]

MA33892B1 - Anticorps anti-her3, et leurs utilisations - Google Patents

Anticorps anti-her3, et leurs utilisations

Info

Publication number
MA33892B1
MA33892B1 MA35018A MA35018A MA33892B1 MA 33892 B1 MA33892 B1 MA 33892B1 MA 35018 A MA35018 A MA 35018A MA 35018 A MA35018 A MA 35018A MA 33892 B1 MA33892 B1 MA 33892B1
Authority
MA
Morocco
Prior art keywords
antibodies against
antibodies
against her3
her3
production
Prior art date
Application number
MA35018A
Other languages
Arabic (ar)
English (en)
Inventor
Birgit Bossenmaier
Nikolaos Dimoudis
Thomas Friess
Guy Georges
Irene Kolm
Hans-Willi Krell
Valeria Lifke
Ekkehard Moessner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42126432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33892(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA33892B1 publication Critical patent/MA33892B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps se liant au HER3 humain (anticorps anti-HER3), des procédés de production correspondants, des compositions pharmaceutiques contenant ces anticorps, et les utilisations de celles-ci.
MA35018A 2009-12-22 2010-12-17 Anticorps anti-her3, et leurs utilisations MA33892B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015831 2009-12-22
PCT/EP2010/070062 WO2011076683A1 (fr) 2009-12-22 2010-12-17 Anticorps anti-her3, et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33892B1 true MA33892B1 (fr) 2013-01-02

Family

ID=42126432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35018A MA33892B1 (fr) 2009-12-22 2010-12-17 Anticorps anti-her3, et leurs utilisations

Country Status (33)

Country Link
US (4) US8859737B2 (fr)
EP (1) EP2516469B1 (fr)
JP (2) JP5680671B2 (fr)
KR (2) KR20140130751A (fr)
CN (1) CN102822201B (fr)
AR (1) AR079551A1 (fr)
AU (1) AU2010335282B2 (fr)
BR (1) BR112012015255A2 (fr)
CA (1) CA2782571C (fr)
CL (1) CL2012001649A1 (fr)
CO (1) CO6551674A2 (fr)
CR (1) CR20120284A (fr)
CY (1) CY1117563T1 (fr)
DK (1) DK2516469T3 (fr)
EC (1) ECSP12011995A (fr)
ES (1) ES2571226T3 (fr)
HR (1) HRP20160737T1 (fr)
HU (1) HUE029026T2 (fr)
IL (1) IL220162A (fr)
MA (1) MA33892B1 (fr)
MX (1) MX2012007340A (fr)
MY (1) MY161909A (fr)
NZ (1) NZ600262A (fr)
PE (1) PE20121616A1 (fr)
PH (1) PH12012501157A1 (fr)
PL (1) PL2516469T3 (fr)
RS (1) RS54795B1 (fr)
RU (1) RU2560583C2 (fr)
SG (1) SG181894A1 (fr)
SI (1) SI2516469T1 (fr)
TW (1) TWI421092B (fr)
UA (1) UA107821C2 (fr)
WO (1) WO2011076683A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
BRPI1012589A2 (pt) * 2009-04-07 2016-03-22 Roche Glycart Ag anticorpos bi-específicos anti-erbb-3/anti-c-met
WO2011076683A1 (fr) * 2009-12-22 2011-06-30 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
ES2648264T3 (es) 2010-03-10 2017-12-29 F. Hoffmann-La Roche Ag Procedimiento para la purificación de soluciones de inmunoglobulinas
WO2011136911A2 (fr) 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anticorps anti-erbb3
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
AU2012215572A1 (en) 2011-02-10 2013-05-02 Roche Glycart Ag Improved immunotherapy
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
CN105884900A (zh) 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
AU2012316402B2 (en) * 2011-09-30 2017-04-20 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
EP2797957B1 (fr) 2011-11-23 2019-06-19 MedImmune, LLC Molécules de liaison propres à her3 et utilisation de celles-ci
WO2013081645A2 (fr) 2011-11-30 2013-06-06 Genentech, Inc. Mutations dans erbb3 dans des cancers
TW201328706A (zh) * 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
EP3434695B1 (fr) 2012-08-07 2020-12-02 Roche Glycart AG Immunothérapie améliorée
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014114595A1 (fr) 2013-01-23 2014-07-31 Roche Glycart Ag Biomarqueur prédictif pour traitement anticancéreux au moyen d'anticorps à activité adcc accrue
EP2968540A2 (fr) 2013-03-14 2016-01-20 Genentech, Inc. Combinaisons d'un composé inhibiteur de mek avec un composé inhibiteur de her3/egfr et procédés d'utilisation
CN105209493B (zh) * 2013-03-14 2019-05-03 德克萨斯州大学系统董事会 用于诊断和治疗用途的her3特异性单克隆抗体
CA2907776C (fr) * 2013-04-16 2020-04-14 Genentech, Inc. Variantes de pertuzumab et leur evaluation
WO2015048008A2 (fr) 2013-09-24 2015-04-02 Medimmune, Llc Molécules de liaison spécifiques de her3 et utilisation desdites molécules
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
WO2015100459A2 (fr) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
WO2015157634A1 (fr) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anticorps anti-erbb et leurs méthodes d'utilisation
JP6695812B2 (ja) 2014-05-14 2020-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
WO2015173250A1 (fr) 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Anticorps anti-her3 se liant à l'épingle à cheveux bêta de her3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3091033A1 (fr) * 2015-05-06 2016-11-09 Gamamabs Pharma Anticorps anti-her3 humains et leurs utilisations
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
SG11201806251WA (en) 2016-03-15 2018-08-30 Merrimack Pharmaceuticals Inc Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
EP3898682A1 (fr) 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0896586B2 (fr) * 1996-03-27 2015-05-20 Genentech, Inc. ANTICORPS DE LA PROTEINE ErbB3
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
DK1176195T3 (da) 1999-04-09 2013-06-24 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1228766A1 (fr) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
US7744882B2 (en) * 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
CA2463879C (fr) 2001-10-25 2012-12-04 Genentech, Inc. Compositions de glycoproteine
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
NZ591970A (en) 2003-01-22 2012-11-30 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
CA2534077A1 (fr) 2003-07-29 2005-02-10 Morphotek Inc. Anticorps et procedes permettant de produire des anticorps genetiquement modifies presentant une fonction effectrice amelioree
EP2502935B1 (fr) 2003-08-22 2017-03-29 Biogen MA Inc. Anticorps améliorés dotés d'une fonction effectrice altérée et leurs procédés de fabrication
EP1663306A2 (fr) 2003-09-05 2006-06-07 Genentech, Inc. Anticorps aux fonctions d'effecteur modifiees
HUE042914T2 (hu) 2003-11-05 2019-07-29 Roche Glycart Ag CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval
JP2008512479A (ja) 2004-09-08 2008-04-24 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びｃｄ２０抗体の使用方法
EP1810035A4 (fr) 2004-11-10 2010-03-17 Macrogenics Inc Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
US20090215639A1 (en) 2005-04-26 2009-08-27 Bioren, Inc. Method of Producing Human IgG Antibodies with Enhanced Effector Functions
TWI478940B (zh) 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
AU2007324868B2 (en) 2006-11-28 2014-03-20 Daiichi Sankyo Europe Gmbh Activated HER3 as a marker for predicting therapeutic efficacy
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2129396B1 (fr) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Anticorps contre erbb3 et leur utilisation
EP2138511A1 (fr) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 en tant que déterminant pour le pronostic de mélanome
EP2318548B1 (fr) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Procédés, systèmes et produits pour prévoir une réponse de cellules tumorales à un agent thérapeutique, et traitement d'un patient selon la réponse prévue
EP2387711B1 (fr) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Procédés permettant de déterminer la réponse d'un patient par mesure de her-3
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
BRPI1012589A2 (pt) * 2009-04-07 2016-03-22 Roche Glycart Ag anticorpos bi-específicos anti-erbb-3/anti-c-met
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
CA2775573A1 (fr) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, caracterisation et utilisations d'anticorps anti-her3
US10208128B2 (en) 2009-11-04 2019-02-19 Affibody Ab HER3 binding polypeptides
ES2781299T3 (es) 2009-11-13 2020-09-01 Daiichi Sankyo Europe Gmbh Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
WO2011076683A1 (fr) * 2009-12-22 2011-06-30 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
WO2011136911A2 (fr) 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anticorps anti-erbb3
WO2012019024A2 (fr) 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
CA2815154A1 (fr) 2010-08-06 2012-02-09 U3 Pharma Gmbh Utilisation d'agents de liaison her3 dans le traitement de la prostate
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012044612A1 (fr) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Génération, caractérisation et utilisations d'anticorps anti-her3
ES2632486T3 (es) 2010-10-18 2017-09-13 Mediapharma S.R.L. Anticuerpo de unión a ErbB3
EP2635604B1 (fr) 2010-11-01 2016-11-30 Symphogen A/S Composition d'antcorps pan-her
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
AU2012316402B2 (en) 2011-09-30 2017-04-20 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof

Also Published As

Publication number Publication date
JP5680671B2 (ja) 2015-03-04
KR20120098911A (ko) 2012-09-05
CO6551674A2 (es) 2012-10-31
CR20120284A (es) 2012-09-04
HUE029026T2 (en) 2017-01-30
CN102822201B (zh) 2014-09-24
HRP20160737T1 (hr) 2016-07-15
CY1117563T1 (el) 2017-04-26
US20140377273A1 (en) 2014-12-25
SI2516469T1 (sl) 2016-05-31
TWI421092B (zh) 2014-01-01
BR112012015255A2 (pt) 2017-01-10
IL220162A (en) 2017-04-30
CA2782571C (fr) 2018-01-23
PL2516469T3 (pl) 2017-08-31
EP2516469B1 (fr) 2016-03-30
US9611331B2 (en) 2017-04-04
MX2012007340A (es) 2012-08-01
JP2015109848A (ja) 2015-06-18
US20110171222A1 (en) 2011-07-14
RU2560583C2 (ru) 2015-08-20
US20170174784A1 (en) 2017-06-22
AU2010335282B2 (en) 2015-05-21
TW201130510A (en) 2011-09-16
HK1175183A1 (en) 2013-06-28
PH12012501157A1 (en) 2012-10-29
RS54795B1 (sr) 2016-10-31
ES2571226T3 (es) 2016-05-24
RU2012129735A (ru) 2014-01-27
UA107821C2 (en) 2015-02-25
SG181894A1 (en) 2012-08-30
JP2013514793A (ja) 2013-05-02
US20140377272A1 (en) 2014-12-25
PE20121616A1 (es) 2012-12-05
IL220162A0 (en) 2012-07-31
US10196456B2 (en) 2019-02-05
CN102822201A (zh) 2012-12-12
KR20140130751A (ko) 2014-11-11
CA2782571A1 (fr) 2011-06-30
AR079551A1 (es) 2012-02-01
MY161909A (en) 2017-05-15
CL2012001649A1 (es) 2012-10-12
ECSP12011995A (es) 2012-07-31
DK2516469T3 (en) 2016-05-02
US8859737B2 (en) 2014-10-14
NZ600262A (en) 2013-06-28
EP2516469A1 (fr) 2012-10-31
WO2011076683A1 (fr) 2011-06-30
AU2010335282A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
MA32895B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
CO6571886A2 (es) Antagonistas de pcsk9
MA33198B1 (fr) Anticorps anti-her di-spécifiques
MA32713B1 (fr) Anticorps anti-egfr/anti-igf-1r bispecifiques
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
MA32896B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et du melphalan
EP2331136A4 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
MA38176A1 (fr) Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
ITTO20110636A1 (it) Composizione farmaceutica e metodo per inibire la produzione o amplificare l'eliminazione della proteina p24